Healthcare Intelligence
Pharma Drug Discovery & R&D
Real-time intelligence, expert analysis, and verified research for the Pharma Drug Discovery & R&D industry. Stay ahead in 3 minutes a day.
Stay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
GCAR & Purdue Pharma Launch Tinostamustine in GBM AGILE Brain Cancer Trial
Tinostamustine enters phase 2/3 adaptive platform trial for glioblastoma patients. Study can potentially support FDA registration.
Read full articleAtaiBeckley's BPL-003 Shows 67% Response Rate in Treatment-Resistant Depression
Single intranasal dose achieved rapid antidepressant response by Day 2. FDA Breakthrough Therapy Designation granted, Phase 3 starts Q2 2026.
Read full articleNovel [225Ac]-Pertuzumab Radioconjugate Shows Promise Against HER2+ Breast Cancer
New alpha-emitting antibody-drug conjugate combines targeted therapy with radiotherapy. Preclinical data shows potent anti-cancer activity.
Read full articleVariational AI Releases Enki 4 Foundation Model for Drug Discovery
AI platform now covers 760 drug targets, up 28% from previous version. Extends to degraders, PROTACs, and ADC payload design.
Read full articleNuvalent Submits NDA for Neladalkib in ALK-Positive Lung Cancer
FDA application based on ALKOVE-1 trial data in TKI pre-treated patients. Drug has breakthrough therapy and orphan drug designations.
Read full articleGCAR & Purdue Pharma Launch Tinostamustine in GBM AGILE Brain Cancer Trial
Tinostamustine enters phase 2/3 adaptive platform trial for glioblastoma patients. Study can potentially support FDA registration.
Read full articleAtaiBeckley's BPL-003 Shows 67% Response Rate in Treatment-Resistant Depression
Single intranasal dose achieved rapid antidepressant response by Day 2. FDA Breakthrough Therapy Designation granted, Phase 3 starts Q2 2026.
Read full articleNovel [225Ac]-Pertuzumab Radioconjugate Shows Promise Against HER2+ Breast Cancer
New alpha-emitting antibody-drug conjugate combines targeted therapy with radiotherapy. Preclinical data shows potent anti-cancer activity.
Read full articleVariational AI Releases Enki 4 Foundation Model for Drug Discovery
AI platform now covers 760 drug targets, up 28% from previous version. Extends to degraders, PROTACs, and ADC payload design.
Read full articleNuvalent Submits NDA for Neladalkib in ALK-Positive Lung Cancer
FDA application based on ALKOVE-1 trial data in TKI pre-treated patients. Drug has breakthrough therapy and orphan drug designations.
Read full articleStay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Expert-verified intelligence on your industry, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.